AHSCT awakens EBV in MS, yet relapse remains at bay
25 October 2023
The first study of EBV immunity shows reactivation of the virus after AHSCT is not related to relapses in MS.
The first study of EBV immunity shows reactivation of the virus after AHSCT is not related to relapses in MS.
Researchers find no significant differences in self-reported sleep quality in individuals who use disease-modifying therapies (DMTs).
Challenge yourself with Australia’s most epic charity cycling event, the MS Gong Ride from Sydney to Wollongong and experience the ride of a lifetime while helping fight multiple sclerosis.
A recent study shows that reactive balance training in a controlled environment can be provided to people with MS. Those who receive the training experience improved trip-induced dynamic stability, limb support and trunk control and a reduced number of falls.
New study explores how relapses in early MS (ROMS) affect disability progression.
By Sharlene Brown, independent Board member and Chair of the National Advocacy Committee for MS Australia This feature piece
A new vaccine developed by Australian researchers is highly effective against Epstein-Barr virus (EBV) in laboratory models, strongly supporting ongoing development for use in humans.
New research shows that stem cell therapy was effective for patients with treatment-resistant, aggressive MS.
The MSBase Study Group has compared the effectiveness of three MS medications as alternative treatment options after discontinuation of natalizumab (Tysabri®).